(IN BRIEF) Boehringer Ingelheim and CDR-Life have expanded their partnership through a global licensing agreement to develop CDR111, a trispecific M-gager® antibody designed to reset the immune system by selectively targeting B cells. The collaboration builds upon their prior success … Read the full press release →
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged antibody-based therapy, Arthritis, autoimmune diseases, B cells, biotechnology, Boehringer Ingelheim, Boehringer Ingelheim and CDR-Life Expand Partnership with New Global Licensing Deal to Advance Autoimmune Disease Therapies, Carine Boustany, CDR-Life, CDR111, Christian Leisner, Geographic Atrophy, global licensing agreement, immune system reset, lupus, multiple sclerosis, pharmaceutical collaboration, T-cell engager, trispecific M-gager, USD 570 million deal, VERDANT Phase 2 trial
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | |
